Apr. 29 at 7:53 PM
$LENZ Hi everyone,
There have been a few SEC filings over the past several days. It’s encouraging to see that BlackRock has increased their position.
I also just returned from an ophthalmology conference in South Korea, along with some time in Taiwan. I don’t have a significant amount of new information to report, as VIZZ is not yet approved in these markets. That said, the expectation in South Korea is that approval could come by the end of the year.
From a broader perspective, South Korea appears to be a very strong potential market for products like VIZZ. There is a high level of interest in appearance-enhancing treatments, and the overall openness to new solutions in this category was very noticeable. The eye doctor that I engaged with were aware of VIZZ and we’re eager to try it.
